Search research articles
Contact Us
Filters
Showing results (221-230 of 251) with videos related to
Page
of 26
Sort By:
Frontiers in Medicine
|
July 20, 2023
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Psoriasis (Auckland, N.Z.)
|
September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Dermatology and Therapy
|
June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis
Luigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.
Clinical and Experimental Dermatology
|
January 13, 2026
Long-Term Effectiveness of Bimekizumab in Plaque Psoriasis: Two-Year Drug Survival from a Real-Life Multicenter Italian Study
Eleonora De Luca, Annunziata Dattola, Fabio Artosi, et al.
Journal of Clinical Medicine
|
January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Clinical and Experimental Dermatology
|
June 16, 2025
Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study
Francesca Satolli, Silvia Gerosa, Martina Burlando, et al.
The Journal of Dermatological Treatment
|
January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort
Diego Orsini, Luca Potestio, Matteo Megna, et al.
The Journal of Dermatological Treatment
|
September 24, 2025
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index
Nicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 251) with videos related to
Sort By:
Page
of 26
Frontiers in Medicine
|
July 20, 2023
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Psoriasis (Auckland, N.Z.)
|
September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Dermatology and Therapy
|
June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis
Luigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.
Clinical and Experimental Dermatology
|
January 13, 2026
Long-Term Effectiveness of Bimekizumab in Plaque Psoriasis: Two-Year Drug Survival from a Real-Life Multicenter Italian Study
Eleonora De Luca, Annunziata Dattola, Fabio Artosi, et al.
Journal of Clinical Medicine
|
January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Clinical and Experimental Dermatology
|
June 16, 2025
Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study
Francesca Satolli, Silvia Gerosa, Martina Burlando, et al.
The Journal of Dermatological Treatment
|
January 23, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort
Diego Orsini, Luca Potestio, Matteo Megna, et al.
The Journal of Dermatological Treatment
|
September 24, 2025
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index
Nicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, et al.
Page
of 26